The study will compare outcomes on J&J’s Varipulse Pro platform and Boston Scientific’s rival Farapulse PFA system.
Johnson & Johnson today announced the initiation of a new trial evaluating competitive pulsed field ablation (PFA) ...
Boston Scientific shared the results during a late-breaking presentation at this year’s EHRA congress in Paris, France.
Boston Scientific (NYSE:BSX) today shared new clinical findings supporting its wide-ranging electrophysiology (EP) portfolio.
Boston Scientific, Abbott and Medtronic shared new cardiac device data at the annual Heart Rhythm Society meeting, where ...
MARLBOROUGH, Mass. and AMSTERDAM, Aug. 27, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month results from the pivotal ADVENT clinical trial of the ...
MedPage Today on MSN
Upfront pulsed field ablation shows efficacy in persistent AFib
AVANT GUARD trial meets expectations despite pause for safety modifications ...
In December 2023, Boston Scientific Corporation (NYSE: BSX) initiated the AVANT GUARD trial to evaluate the safety and effectiveness of the FARAPULSE Pulsed Field Ablation (PFA) System as a first-line ...
MARLBOROUGH, Mass., Sept. 27, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced it has received Pharmaceuticals and Medical Device Agency (PMDA) approval in Japan for the ...
MARLBOROUGH, Mass. and SAN DIEGO, April 24, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month primary endpoint results from the second phase of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results